ABEO Abeona Therapeutics Inc

USD 7.53 -0.40 -5.044136
Icon

Abeona Therapeutics Inc (ABEO) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 7.53

-0.40 (-5.04)%

USD 0.21B

0.25M

N/A

USD 3.00 (-60.16%)

Icon

ABEO

Abeona Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 7.53
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.21B

USD 3.00 (-60.16%)

USD 7.53

Abeona Therapeutics Inc (ABEO) Stock Forecast

N/A

Based on the Abeona Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Abeona Therapeutics Inc is not available over the next 12 months. Abeona Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Abeona Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Abeona Therapeutics Inc’s stock price was USD 7.53. Abeona Therapeutics Inc’s stock price has changed by -3.34% over the past week, +7.73% over the past month and +157.00% over the last year.

No recent analyst target price found for Abeona Therapeutics Inc
No recent average analyst rating found for Abeona Therapeutics Inc

Company Overview Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermol...Read More

1330 Avenue of the Americas, New York, NY, United States, 10019

84

December

USD

USA

Adjusted Closing Price for Abeona Therapeutics Inc (ABEO)

Loading...

Unadjusted Closing Price for Abeona Therapeutics Inc (ABEO)

Loading...

Share Trading Volume for Abeona Therapeutics Inc Shares

Loading...

Compare Performance of Abeona Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ABEO

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Abeona Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.38 (+0.10%) USD107.38B 29.93 21.06

ETFs Containing ABEO

Symbol Name ABEO's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Abeona Therapeutics Inc (ABEO) Stock

Stock Target Advisor's fundamental analysis for Abeona Therapeutics Inc's stock is Bearish.

Unfortunately we do not have enough data on ABEO's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ABEO's stock to indicate what its average analyst target is.

ABEO stock's Price/Earning ratio is 17.70. Our analysis grades ABEO stock's Price / Earning ratio at F. This means that ABEO stock's Price/Earning ratio is above 69% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABEO may be a overvalued for its sector.

The last closing price of ABEO's stock was USD 7.53.

The most recent market capitalization for ABEO is USD 0.21B.

Unfortunately we do not have enough analyst data on ABEO's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Abeona Therapeutics Inc's stock.

As per our most recent records Abeona Therapeutics Inc has 84 Employees.

Abeona Therapeutics Inc's registered address is 1330 Avenue of the Americas, New York, NY, United States, 10019. You can get more information about it from Abeona Therapeutics Inc's website at https://www.abeonatherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...